-
1
-
-
0028708678
-
Clinical pharmacology and metabolism of Taxol (paclitaxel): Update 1993
-
Rowinsky, E. K.; Wright, M.; Monsarrat, B.; Donehower, R. C. Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. Ann. Oncol. 1994, 5(Suppl. 6), S7-S16.
-
(1994)
Ann. Oncol
, vol.5
, Issue.SUPPL. 6
-
-
Rowinsky, E.K.1
Wright, M.2
Monsarrat, B.3
Donehower, R.C.4
-
2
-
-
0027950826
-
Taxol (paclitaxel): A novel anti-microtubule agent with remarkable anti-neoplastic activity
-
Foa, R.; Norton, L.; Seidman, A. D. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int. J. Clin. Lab. Res. 1994, 24, 6-14.
-
(1994)
Int. J. Clin. Lab. Res
, vol.24
, pp. 6-14
-
-
Foa, R.1
Norton, L.2
Seidman, A.D.3
-
3
-
-
0031040149
-
The development and clinical utility of the taxane class on antimicrotubule chemotherapy agents
-
Rowinsky, E. K. The development and clinical utility of the taxane class on antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997, 48, 353-374.
-
(1997)
Annu. Rev. Med
, vol.48
, pp. 353-374
-
-
Rowinsky, E.K.1
-
4
-
-
13844256938
-
Treatments of AIDS-related Kaposi's sarcoma
-
Aversa, S. M.; Cattelan, A. M.; Salvagno, L.; Crivellari, G.; Banna, G.; Trevenzoli, M.; Chiarion-Sileni, V.; Monfardini, S. Treatments of AIDS-related Kaposi's sarcoma. Crit. Rev. Oncol. Hematol. 2005, 53, 253-265.
-
(2005)
Crit. Rev. Oncol. Hematol
, vol.53
, pp. 253-265
-
-
Aversa, S.M.1
Cattelan, A.M.2
Salvagno, L.3
Crivellari, G.4
Banna, G.5
Trevenzoli, M.6
Chiarion-Sileni, V.7
Monfardini, S.8
-
5
-
-
17544364644
-
Paclitaxel for AIDS-associated Kaposi's sarcoma
-
Dhillon, T.; Stebbing, J.; Bower, M. Paclitaxel for AIDS-associated Kaposi's sarcoma. Expert Rev. Anticancer Ther. 2005, 5, 215-219.
-
(2005)
Expert Rev. Anticancer Ther
, vol.5
, pp. 215-219
-
-
Dhillon, T.1
Stebbing, J.2
Bower, M.3
-
6
-
-
33644977631
-
Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches
-
Are, C.; Shaha, A. R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann. Surg. Oncol. 2006, 13, 453-464.
-
(2006)
Ann. Surg. Oncol
, vol.13
, pp. 453-464
-
-
Are, C.1
Shaha, A.R.2
-
7
-
-
33751247035
-
Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins
-
Hamada, H.; Ishihara, K.; Masuoka, N.; Mikuni, K.; Nakajima, N. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J. Biosci. Bioeng. 2006, 102, 369-371.
-
(2006)
J. Biosci. Bioeng
, vol.102
, pp. 369-371
-
-
Hamada, H.1
Ishihara, K.2
Masuoka, N.3
Mikuni, K.4
Nakajima, N.5
-
8
-
-
0027228024
-
Clinical toxicities encountered with paclitaxel (Taxol)
-
Rowinsky, E. K.; Eisenhauer, E. A.; Chaudhry, V.; Arbuck, S. G.; Donehower, R. C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 1993, 20(Suppl 3), 1-15.
-
(1993)
Semin. Oncol
, vol.20
, Issue.SUPPL. 3
, pp. 1-15
-
-
Rowinsky, E.K.1
Eisenhauer, E.A.2
Chaudhry, V.3
Arbuck, S.G.4
Donehower, R.C.5
-
9
-
-
0028335032
-
Pharmacology and toxicology of Cremophor EL diluent
-
Dorr, R. T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 1994, 28, S11-S14.
-
(1994)
Ann. Pharmacother
, vol.28
-
-
Dorr, R.T.1
-
11
-
-
38949108587
-
Recent Developments in Taxane Drug Delivery
-
Safavy, A. Recent Developments in Taxane Drug Delivery. Curr. Drug Deliv. 2008, 5, 42-54.
-
(2008)
Curr. Drug Deliv
, vol.5
, pp. 42-54
-
-
Safavy, A.1
-
12
-
-
34447545904
-
Novel enhanced delivery taxanes: An update
-
Perez, E. A. Novel enhanced delivery taxanes: an update. Semin. Oncol. 2007, 34(Suppl.), 1-5.
-
(2007)
Semin. Oncol
, vol.34
, Issue.SUPPL.
, pp. 1-5
-
-
Perez, E.A.1
-
13
-
-
0025311968
-
In vitro and in vivo antitumoral activity of free and encapsulated taxol
-
Bartoli, H.; Boitard, M.; Fessi, H.; Beriel, H.; Devissagnet, J. P.; Picot, F.; Puisien, F. In vitro and in vivo antitumoral activity of free and encapsulated taxol. J. Microencapsulation 1990, 7, 191-197.
-
(1990)
J. Microencapsulation
, vol.7
, pp. 191-197
-
-
Bartoli, H.1
Boitard, M.2
Fessi, H.3
Beriel, H.4
Devissagnet, J.P.5
Picot, F.6
Puisien, F.7
-
14
-
-
33745386420
-
Enhanced oral paclitaxel bioavailability after administration of pacli- taxel-loaded lipid nanocapsules
-
Peltier, S.; Oger, J. M.; Lagarce, F.; Couet, W.; Benoit, J. P. Enhanced oral paclitaxel bioavailability after administration of pacli- taxel-loaded lipid nanocapsules. Pharm. Res. 2006, 23, 1243-1250.
-
(2006)
Pharm. Res
, vol.23
, pp. 1243-1250
-
-
Peltier, S.1
Oger, J.M.2
Lagarce, F.3
Couet, W.4
Benoit, J.P.5
-
15
-
-
0028280464
-
A mixed micellar formulation suitable for parenteral administration of taxol
-
Onyuksel, H.; Ramakrishanan, S.; Chai, H. B.; Pezzuto, J. M. A mixed micellar formulation suitable for parenteral administration of taxol. Pharm. Res. 1994, 11, 206-212.
-
(1994)
Pharm. Res
, vol.11
, pp. 206-212
-
-
Onyuksel, H.1
Ramakrishanan, S.2
Chai, H.B.3
Pezzuto, J.M.4
-
16
-
-
0033964804
-
Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes
-
Crosasso, P.; Ceruti, M.; Brusa, P.; Arpicco, S.; Dosio, F.; Cattel, L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release 2000, 63, 19-30.
-
(2000)
J. Control. Release
, vol.63
, pp. 19-30
-
-
Crosasso, P.1
Ceruti, M.2
Brusa, P.3
Arpicco, S.4
Dosio, F.5
Cattel, L.6
-
17
-
-
34447312229
-
Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome
-
Yang, T.; Choi, M. K.; Cui, F. D.; Kim, J. S.; Chung, S. J.; Shim, C. K.; Kim, D. D. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J. Control. Release 2007, 120, 169-177.
-
(2007)
J. Control. Release
, vol.120
, pp. 169-177
-
-
Yang, T.1
Choi, M.K.2
Cui, F.D.3
Kim, J.S.4
Chung, S.J.5
Shim, C.K.6
Kim, D.D.7
-
18
-
-
0030947239
-
Preparation, characterization and properties in vitro and in vivo of pacli- taxel-albumin conjugate
-
Dosio, F.; Brusa, P.; Crosasso, P.; Arpicco, S.; Cattel, L. Preparation, characterization and properties in vitro and in vivo of pacli- taxel-albumin conjugate. J. Contr. Release 1997, 47, 293-304.
-
(1997)
J. Contr. Release
, vol.47
, pp. 293-304
-
-
Dosio, F.1
Brusa, P.2
Crosasso, P.3
Arpicco, S.4
Cattel, L.5
-
19
-
-
0028896964
-
-
Burt, H.; Jackson, J. K.; Sarvjeet, B. K.; Liggins, R. T.; Oktaba, A. M.; Arsenault, L. A; Hunter, W. L. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (D,L-lactic acid). Cancer Lett. 1995, 88, 73-79.
-
Burt, H.; Jackson, J. K.; Sarvjeet, B. K.; Liggins, R. T.; Oktaba, A. M.; Arsenault, L. A; Hunter, W. L. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (D,L-lactic acid). Cancer Lett. 1995, 88, 73-79.
-
-
-
-
20
-
-
0023165070
-
A new parenteral emulsion for administration of taxol
-
Tarr, B.; Sambandan, T. G.; Yalkowsky, S. H. A new parenteral emulsion for administration of taxol. Pharm. Res. 1987, 4, 162-165.
-
(1987)
Pharm. Res
, vol.4
, pp. 162-165
-
-
Tarr, B.1
Sambandan, T.G.2
Yalkowsky, S.H.3
-
21
-
-
0031033405
-
A submicron lipid emulsion coated with amphi- patic polyethylene glycol for parenteral administration of paclitaxel (taxol)
-
Lundberg, B. B. A submicron lipid emulsion coated with amphi- patic polyethylene glycol for parenteral administration of paclitaxel (taxol). J. Pharm. Pharmacol. 1997, 49, 16-21.
-
(1997)
J. Pharm. Pharmacol
, vol.49
, pp. 16-21
-
-
Lundberg, B.B.1
-
22
-
-
1542291181
-
Nanoparticles of biodegradable polymers for clinical administration of paclitaxel
-
Feng, S. S.; Mu, L.; Win, K. Y.; Huang, G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 2004, 11, 413-424.
-
(2004)
Curr. Med. Chem
, vol.11
, pp. 413-424
-
-
Feng, S.S.1
Mu, L.2
Win, K.Y.3
Huang, G.4
-
23
-
-
33344466821
-
Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel
-
Kim, J. H.; Kim, Y. S.; Kim, S.; Park, J. H.; Kim, K.; Choi, K.; Chung, H.; Jeong, S. Y.; Park, R. W.; Kim, I. S.; Kwon, I. C. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Release 2006, 111, 228-234.
-
(2006)
J. Control. Release
, vol.111
, pp. 228-234
-
-
Kim, J.H.1
Kim, Y.S.2
Kim, S.3
Park, J.H.4
Kim, K.5
Choi, K.6
Chung, H.7
Jeong, S.Y.8
Park, R.W.9
Kim, I.S.10
Kwon, I.C.11
-
24
-
-
33750036999
-
Lyoprotected nanosphere formulations for paclitaxel controlled delivery
-
Musumeci, T.; Vicari, L.; Ventura, C. A.; Gulisano, M.; Pignatello, R.; Puglisi, G. Lyoprotected nanosphere formulations for paclitaxel controlled delivery. J. Nanosci. Nanotech. 2006, 6, 3118-3125.
-
(2006)
J. Nanosci. Nanotech
, vol.6
, pp. 3118-3125
-
-
Musumeci, T.1
Vicari, L.2
Ventura, C.A.3
Gulisano, M.4
Pignatello, R.5
Puglisi, G.6
-
25
-
-
33745423724
-
Phar- macokinetics and biodistribution of polymeric micelles of pacli- taxel with Pluronic P123
-
Han, L. M.; Guo, J.; Zhang, L. J.; Wang, Q. S.; Fang, X. L. Phar- macokinetics and biodistribution of polymeric micelles of pacli- taxel with Pluronic P123. Acta Pharmacol. Sin. 2006, 27, 747-753.
-
(2006)
Acta Pharmacol. Sin
, vol.27
, pp. 747-753
-
-
Han, L.M.1
Guo, J.2
Zhang, L.J.3
Wang, Q.S.4
Fang, X.L.5
-
26
-
-
56949084877
-
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
-
Epub ahead of print
-
Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008 [Epub ahead of print].
-
(2008)
J. Control. Release
-
-
Kratz, F.1
-
27
-
-
33745458519
-
Albumin-bound paclitaxel: A next-generation taxane
-
Gradishar, W. J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 2006, 7, 1041-1053.
-
(2006)
Expert Opin. Pharmacother
, vol.7
, pp. 1041-1053
-
-
Gradishar, W.J.1
-
28
-
-
34548563733
-
Using nanotechnology to improve the characteristics of antineoplastic drugs: Improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel
-
Foote, M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol. Annu. Rev. 2007, 13, 345-357.
-
(2007)
Biotechnol. Annu. Rev
, vol.13
, pp. 345-357
-
-
Foote, M.1
-
29
-
-
0037619168
-
Poly-(L)-glutamic acid- paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: Characterization, preclinical pharmacology, and preliminary clinical data
-
Singer, J. W.; Baker, B.; De Vries, P.; Kumar, A.; Shaffer, S.; Vawter, E.; Bolton, M.; Garzone, P. Poly-(L)-glutamic acid- paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 2003, 519, 81-99.
-
(2003)
Adv. Exp. Med. Biol
, vol.519
, pp. 81-99
-
-
Singer, J.W.1
Baker, B.2
De Vries, P.3
Kumar, A.4
Shaffer, S.5
Vawter, E.6
Bolton, M.7
Garzone, P.8
-
30
-
-
34548626932
-
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate
-
Chipman, S. D.; Oldham, F. B.; Pezzoni, G.; Singer, J. W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int. J. Nanomed. 2006, 1, 375-383.
-
(2006)
Int. J. Nanomed
, vol.1
, pp. 375-383
-
-
Chipman, S.D.1
Oldham, F.B.2
Pezzoni, G.3
Singer, J.W.4
-
31
-
-
34247629652
-
Paclitaxel poliglumex (PPX, CT-2103): Macromolecu- lar medicine for advanced non-small-cell lung cancer
-
Bonomi, P. Paclitaxel poliglumex (PPX, CT-2103): macromolecu- lar medicine for advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2007, 7, 415-422.
-
(2007)
Expert Rev. Anticancer Ther
, vol.7
, pp. 415-422
-
-
Bonomi, P.1
-
32
-
-
43649092756
-
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
-
Paz-Ares, L.; Ross, H.; O'Brien, M.; Riviere, A.; Gatzemeier, U.; Von Pawel, J.; Kaukel, E.; Freitag, L.; Digel, W.; Bischoff, H.; Garcia-Campelo, R.; Iannotti, N.; Reiterer, P.; Bover, I.; Pren- diville, J.; Eisenfeld, A. J.; Oldham, F. B.; Bandstra, B.; Singer, J. W.; Bonomi, P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer 2008, 98, 1608-1613.
-
(2008)
Br. J. Cancer
, vol.98
, pp. 1608-1613
-
-
Paz-Ares, L.1
Ross, H.2
O'Brien, M.3
Riviere, A.4
Gatzemeier, U.5
Von Pawel, J.6
Kaukel, E.7
Freitag, L.8
Digel, W.9
Bischoff, H.10
Garcia-Campelo, R.11
Iannotti, N.12
Reiterer, P.13
Bover, I.14
Pren- diville, J.15
Eisenfeld, A.J.16
Oldham, F.B.17
Bandstra, B.18
Singer, J.W.19
Bonomi, P.20
more..
-
33
-
-
50149116962
-
Gynecologic Oncology Group. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: A phase I and feasibility trial of the Gynecologic Oncology Group
-
Morgan, M. A.; Darcy, K. M.; Rose, P. G.; DeGeest, K.; Bookman, M.A.; Aikins, J. K.; Sill, M. W.; Mannel, R. S.; Allievi, C.; Egorin, M. J.; Gynecologic Oncology Group. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol. Oncol. 2008, 110, 329-335.
-
(2008)
Gynecol. Oncol
, vol.110
, pp. 329-335
-
-
Morgan, M.A.1
Darcy, K.M.2
Rose, P.G.3
DeGeest, K.4
Bookman, M.A.5
Aikins, J.K.6
Sill, M.W.7
Mannel, R.S.8
Allievi, C.9
Egorin, M.J.10
-
34
-
-
44349123949
-
Synthesis and evaluation of water-soluble poly(vinyl alcohol)-paclitaxel conjugate as a macromolecular prodrug
-
Kakinoki, A.; Kaneo, Y.; Tanaka, T.; Hosokawa, Y. Synthesis and evaluation of water-soluble poly(vinyl alcohol)-paclitaxel conjugate as a macromolecular prodrug. Biol. Pharm. Bull. 2008, 31, 963-996.
-
(2008)
Biol. Pharm. Bull
, vol.31
, pp. 963-996
-
-
Kakinoki, A.1
Kaneo, Y.2
Tanaka, T.3
Hosokawa, Y.4
-
35
-
-
0030071043
-
Drug delivery systems: Water soluble taxol 2'- poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness
-
Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: water soluble taxol 2'- poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 1996, 39, 424-431.
-
(1996)
J. Med. Chem
, vol.39
, pp. 424-431
-
-
Greenwald, R.B.1
Gilbert, C.W.2
Pendri, A.3
Conover, C.D.4
Xia, J.5
Martinez, A.6
-
36
-
-
0031857631
-
Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): A water- soluble prodrug
-
Pendri, A.; Conover, C. D.; Greenwald, R. B. Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water- soluble prodrug. Anticancer Drug Des. 1998, 13, 387-395.
-
(1998)
Anticancer Drug Des
, vol.13
, pp. 387-395
-
-
Pendri, A.1
Conover, C.D.2
Greenwald, R.B.3
-
37
-
-
3242736466
-
Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats
-
Choi, J. -S.; Jo, B. -W. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int. J. Pharm. 2004, 280, 221-227.
-
(2004)
Int. J. Pharm
, vol.280
, pp. 221-227
-
-
Choi, J.-S.1
Jo, B.-W.2
-
38
-
-
1442359716
-
Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pre- treated with quercetin
-
Choi, J. -S.; Jo, B. -W.; Kim, Y. -C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pre- treated with quercetin. Eur. J. Pharm. Biopharm. 2004, 57, 313-318.
-
(2004)
Eur. J. Pharm. Biopharm
, vol.57
, pp. 313-318
-
-
Choi, J.-S.1
Jo, B.-W.2
Kim, Y.-C.3
-
39
-
-
23744480026
-
Anti-tumor activity of paclitaxel prodrug conjugated with polyethylene glycol
-
Lee, K. H.; Chung, Y. J.; Kim, Y. -C.; Song, S. J. Anti-tumor activity of paclitaxel prodrug conjugated with polyethylene glycol. Bull. Korean Chem. Soc. 2005, 26, 1079-1082.
-
(2005)
Bull. Korean Chem. Soc
, vol.26
, pp. 1079-1082
-
-
Lee, K.H.1
Chung, Y.J.2
Kim, Y.-C.3
Song, S.J.4
-
40
-
-
33845508580
-
Paclitaxel Prodrugs: Toward Smarter Delivery of Anticancer Agents
-
Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel Prodrugs: Toward Smarter Delivery of Anticancer Agents. J. Med. Chem. 2006, 49, 7253-7269.
-
(2006)
J. Med. Chem
, vol.49
, pp. 7253-7269
-
-
Skwarczynski, M.1
Hayashi, Y.2
Kiso, Y.3
-
41
-
-
0033253860
-
Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice
-
Ahmad, I.; Masters, G. R.; Schupsky, J. J.; Nguyen, J.; Ali, S.; Janoff, A. S.; Mayhew, E. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice. Oncol. Res. 1999, 11, 273-280.
-
(1999)
Oncol. Res
, vol.11
, pp. 273-280
-
-
Ahmad, I.1
Masters, G.R.2
Schupsky, J.J.3
Nguyen, J.4
Ali, S.5
Janoff, A.S.6
Mayhew, E.7
-
42
-
-
0035816158
-
Tumor targeting by conjugation of DHA to paclitaxel
-
Bradley, M. O.; Swindell, C. S.; Anthony, F. H.; Witnam, P. A.; Devanesan, P.; Webb, N. L.; Baker, S. D.; Wolff, A. C.; Donehower, R. C. Tumor targeting by conjugation of DHA to paclitaxel. J. Contr. Release 2001, 74, 233-236.
-
(2001)
J. Contr. Release
, vol.74
, pp. 233-236
-
-
Bradley, M.O.1
Swindell, C.S.2
Anthony, F.H.3
Witnam, P.A.4
Devanesan, P.5
Webb, N.L.6
Baker, S.D.7
Wolff, A.C.8
Donehower, R.C.9
-
43
-
-
44949198237
-
Modulating the Therapeutic Activity of Nanoparticle Delivered Pa- clitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates
-
Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. O.; Harasym, N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prud'homme, R. K.; Mayer, L. D. Modulating the Therapeutic Activity of Nanoparticle Delivered Pa- clitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates. J. Med. Chem. 2008, 51, 3288-3296.
-
(2008)
J. Med. Chem
, vol.51
, pp. 3288-3296
-
-
Ansell, S.M.1
Johnstone, S.A.2
Tardi, P.G.3
Lo, L.4
Xie, S.5
Shu, Y.6
Harasym, T.O.7
Harasym, N.L.8
Williams, L.9
Bermudes, D.10
Liboiron, B.D.11
Saad, W.12
Prud'homme, R.K.13
Mayer, L.D.14
-
44
-
-
38049110236
-
Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon- caprolactone) micelle nanocarriers: Pharmacokinetic disposition, tolerability, and cytotoxicity
-
Forrest, M. L.; Yanez, J. A.; Remsberg, C. M.; Ohgami, Y.; Kwon, G. S.; Davies, N. M. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon- caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm. Res. 2008, 25, 194-206.
-
(2008)
Pharm. Res
, vol.25
, pp. 194-206
-
-
Forrest, M.L.1
Yanez, J.A.2
Remsberg, C.M.3
Ohgami, Y.4
Kwon, G.S.5
Davies, N.M.6
-
45
-
-
17644366858
-
A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug
-
Stevens, P. J.; Sekido, M.; Lee, R. J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 2004, 21, 2153-2157.
-
(2004)
Pharm. Res
, vol.21
, pp. 2153-2157
-
-
Stevens, P.J.1
Sekido, M.2
Lee, R.J.3
-
46
-
-
36049049858
-
Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme
-
Nikanjam, M.; Gibbs, A. R.; Hunt, C. A.; Budinger, T. F.; Forte, T. M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control. Release 2007, 124, 163-171.
-
(2007)
J. Control. Release
, vol.124
, pp. 163-171
-
-
Nikanjam, M.1
Gibbs, A.R.2
Hunt, C.A.3
Budinger, T.F.4
Forte, T.M.5
-
47
-
-
0028067744
-
A novel chemical approach to drug delivery: Lipid amino acid conjugates
-
Toth, I. A novel chemical approach to drug delivery: lipid amino acid conjugates. J. Drug Target 1994, 2, 217-239.
-
(1994)
J. Drug Target
, vol.2
, pp. 217-239
-
-
Toth, I.1
-
48
-
-
0034935071
-
Lipid, sugar and liposaccharide based delivery systems
-
Wong, A.; Toth, I. Lipid, sugar and liposaccharide based delivery systems. Curr. Med. Chem. 2001, 8, 1123-1136.
-
(2001)
Curr. Med. Chem
, vol.8
, pp. 1123-1136
-
-
Wong, A.1
Toth, I.2
-
49
-
-
4444244953
-
Lipid, sugar and liposaccharide based delivery systems 2
-
Blanchfield, J.; Toth, I. Lipid, sugar and liposaccharide based delivery systems 2. Curr. Med. Chem. 2004, 11, 2375-2382.
-
(2004)
Curr. Med. Chem
, vol.11
, pp. 2375-2382
-
-
Blanchfield, J.1
Toth, I.2
-
50
-
-
0026564126
-
-
Wood, I. P.; Toth, I.; Halley, J. L.; Gibbons, W. A. Lipidic peptides. XIII. Synthesis, structure elucidation, and in vitro toxicity assessment of chlorambucil conjugates with lipidic acids, lipidic amino acids and their oligomers. Int. J. Pharm. 1992, 87, 141-147.
-
Wood, I. P.; Toth, I.; Halley, J. L.; Gibbons, W. A. Lipidic peptides. XIII. Synthesis, structure elucidation, and in vitro toxicity assessment of chlorambucil conjugates with lipidic acids, lipidic amino acids and their oligomers. Int. J. Pharm. 1992, 87, 141-147.
-
-
-
-
51
-
-
0031900337
-
Lipoamino acid conjugates of methotrexate with antitumor activity
-
Pignatello, R.; Jansen, G.; Kathmann, I.; Puglisi, G.; Toth, I. Lipoamino acid conjugates of methotrexate with antitumor activity. J. Pharm. Sci. 1998, 87, 367-371.
-
(1998)
J. Pharm. Sci
, vol.87
, pp. 367-371
-
-
Pignatello, R.1
Jansen, G.2
Kathmann, I.3
Puglisi, G.4
Toth, I.5
-
52
-
-
0034126277
-
-
Pignatello, R.; Spampinato, G.; Sorrenti, V.; Di Giacomo, C.; Vi- cari, L.; McGuire, J. J.; Russell, C. A.; Puglisi, G.; Toth, I. Lipo- philic methotrexate conjugates with antitumor activity. Eur. J. Pharm. Sci. 2000, 10, 237-245.
-
Pignatello, R.; Spampinato, G.; Sorrenti, V.; Di Giacomo, C.; Vi- cari, L.; McGuire, J. J.; Russell, C. A.; Puglisi, G.; Toth, I. Lipo- philic methotrexate conjugates with antitumor activity. Eur. J. Pharm. Sci. 2000, 10, 237-245.
-
-
-
-
53
-
-
0034969204
-
Lipophilic methotrexate conjugates with glucose-lipoamino acid moieties: Synthesis and in vitro anti- tumor activity
-
Pignatello, R.; Vicari, L.; Sorrenti, V.; Di Giacomo, C.; Spampi- nato, G.; Puglisi, G.; Toth, I. Lipophilic methotrexate conjugates with glucose-lipoamino acid moieties: synthesis and in vitro anti- tumor activity. Drug Dev. Res. 2001, 52, 454-464.
-
(2001)
Drug Dev. Res
, vol.52
, pp. 454-464
-
-
Pignatello, R.1
Vicari, L.2
Sorrenti, V.3
Di Giacomo, C.4
Spampi- nato, G.5
Puglisi, G.6
Toth, I.7
-
54
-
-
2442549560
-
Lipo- philic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling
-
Pignatello, R.; Guccione, S.; Forte, S.; Di Giacomo, C.; Sorrenti, V.; Vicari, L.; Uccello Barretta, G.; Balzano, F.; Puglisi, G. Lipo- philic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling. Bioorg. Med. Chem. 2004, 12, 2951-2964.
-
(2004)
Bioorg. Med. Chem
, vol.12
, pp. 2951-2964
-
-
Pignatello, R.1
Guccione, S.2
Forte, S.3
Di Giacomo, C.4
Sorrenti, V.5
Vicari, L.6
Uccello Barretta, G.7
Balzano, F.8
Puglisi, G.9
-
55
-
-
2942685195
-
Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug
-
Cavallaro, G.; Licciardi, M.; Caliceti, P.; Salmaso, S.; Giammona, G. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur. J. Pharm. Biopharm. 2004, 58, 151-159.
-
(2004)
Eur. J. Pharm. Biopharm
, vol.58
, pp. 151-159
-
-
Cavallaro, G.1
Licciardi, M.2
Caliceti, P.3
Salmaso, S.4
Giammona, G.5
-
56
-
-
0027455042
-
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas
-
Fagin, J. A.; Matsuo, K.; Karmakar, A.; Chen, D. L.; Tang, S. H.; Koeffler, H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993, 91, 179-184.
-
(1993)
J. Clin. Invest
, vol.91
, pp. 179-184
-
-
Fagin, J.A.1
Matsuo, K.2
Karmakar, A.3
Chen, D.L.4
Tang, S.H.5
Koeffler, H.P.6
-
57
-
-
0031752682
-
Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches
-
Ain, K. B. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998, 8, 715-726.
-
(1998)
Thyroid
, vol.8
, pp. 715-726
-
-
Ain, K.B.1
-
58
-
-
0037249255
-
Anaplastic thyroid cancer
-
Pasieka, J. L. Anaplastic thyroid cancer. Curr. Opin. Oncol. 2003, 75, 78-83.
-
(2003)
Curr. Opin. Oncol
, vol.75
, pp. 78-83
-
-
Pasieka, J.L.1
-
59
-
-
0029823530
-
Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo
-
Ain, K. B.; Tofiq, S.; Taylor, K. D. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J. Clin. Endocrinol. Metab. 1996, 87, 3650-3653.
-
(1996)
J. Clin. Endocrinol. Metab
, vol.87
, pp. 3650-3653
-
-
Ain, K.B.1
Tofiq, S.2
Taylor, K.D.3
-
60
-
-
0033840233
-
Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six- hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group
-
Ain, K. B.; Egorin, M. J.; De Simone, P. A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six- hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid2000, 10, 587-594.
-
(2000)
Thyroid
, vol.10
, pp. 587-594
-
-
Ain, K.B.1
Egorin, M.J.2
De Simone, P.A.3
-
61
-
-
34547730849
-
Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model
-
Yeung, S. C.; She, M.; Yang, H.; Pan, J.; Sun, L.; Chaplin, D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 2007, 92, 2902-2909.
-
(2007)
J. Clin. Endocrinol. Metab
, vol.92
, pp. 2902-2909
-
-
Yeung, S.C.1
She, M.2
Yang, H.3
Pan, J.4
Sun, L.5
Chaplin, D.6
-
62
-
-
0035040127
-
Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma
-
Xu, G.; Pan, J.; Martin, C.; Yeung, S. C. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J. Clin. Endocrinol. Metab. 2001, 86, 1769-1777.
-
(2001)
J. Clin. Endocrinol. Metab
, vol.86
, pp. 1769-1777
-
-
Xu, G.1
Pan, J.2
Martin, C.3
Yeung, S.C.4
-
63
-
-
33646149656
-
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1
-
Copland, J. A.; Marlow, L. A.; Kurakata, S.; Fujiwara, K.; Wong, A. K.; Kreinest, P. A.; Williams, S. F.; Haugen, B. R.; Klopper, J. P.; Smallridge, R. C. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006, 25, 2304-2317.
-
(2006)
Oncogene
, vol.25
, pp. 2304-2317
-
-
Copland, J.A.1
Marlow, L.A.2
Kurakata, S.3
Fujiwara, K.4
Wong, A.K.5
Kreinest, P.A.6
Williams, S.F.7
Haugen, B.R.8
Klopper, J.P.9
Smallridge, R.C.10
-
64
-
-
0141786825
-
Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the of chemotherapeutics agents in vitro
-
Mahoney, B. P.; Raghunand, N.; Baggett, B.; Gillies, R. J. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the of chemotherapeutics agents in vitro. Biochem. Pharmacol. 2003, 66, 1207-1218.
-
(2003)
Biochem. Pharmacol
, vol.66
, pp. 1207-1218
-
-
Mahoney, B.P.1
Raghunand, N.2
Baggett, B.3
Gillies, R.J.4
-
65
-
-
0032789521
-
Determinants of paclitaxel penetration and accumulation in human solid tumor
-
Kuh, H. J.; Jang, S. H.; Wientjes, M. G.; Weaver, J. R.; Au, J. L. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. Exp. Ther. 1999, 290, 871-880.
-
(1999)
J. Pharmacol. Exp. Ther
, vol.290
, pp. 871-880
-
-
Kuh, H.J.1
Jang, S.H.2
Wientjes, M.G.3
Weaver, J.R.4
Au, J.L.5
-
66
-
-
0036351238
-
Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer
-
Kamazawa, S.; Kigawa, J.; Kanamori, Y.; Itamochi, H.; Sato, S.; Iba, T.; Terakawa, N. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol. Oncol. 2002, 86, 171-176.
-
(2002)
Gynecol. Oncol
, vol.86
, pp. 171-176
-
-
Kamazawa, S.1
Kigawa, J.2
Kanamori, Y.3
Itamochi, H.4
Sato, S.5
Iba, T.6
Terakawa, N.7
-
67
-
-
34247237746
-
-
Parry, S.; Zhang, J. Multidrug resistance proteins affect drug transmission across the placenta. Am. J. Obstet. Gynecol. 2007, 196, 476.e1-e6.
-
Parry, S.; Zhang, J. Multidrug resistance proteins affect drug transmission across the placenta. Am. J. Obstet. Gynecol. 2007, 196, 476.e1-e6.
-
-
-
-
68
-
-
1542346470
-
The influence of enaminones on the transport and oral bioavailability of P- glycoprotein substrate therapeutic agents
-
Salama, N. N.; Scott, K. R.; Eddington, N. D. The influence of enaminones on the transport and oral bioavailability of P- glycoprotein substrate therapeutic agents. Int. J. Pharm. 2004, 273, 135-147.
-
(2004)
Int. J. Pharm
, vol.273
, pp. 135-147
-
-
Salama, N.N.1
Scott, K.R.2
Eddington, N.D.3
-
69
-
-
18144399975
-
Clinical pharmacogenetics of immuno- suppressive drugs in organ transplantation
-
Szekeres, T.; Haushofer, A. Clinical pharmacogenetics of immuno- suppressive drugs in organ transplantation. Pharmacogenomics 2005, 6, 163-168.
-
(2005)
Pharmacogenomics
, vol.6
, pp. 163-168
-
-
Szekeres, T.1
Haushofer, A.2
-
70
-
-
34247388751
-
Expression of ABC- transporters in human corneal tissue and the transformed cell line, HCE-T
-
Becker, U.; Ehrhardt, C.; Daum, N.; Baldes, C.; Schaefer, U. F.; Ruprecht, K. W.; Kim, K. W.; Lehr, C. M. Expression of ABC- transporters in human corneal tissue and the transformed cell line, HCE-T. J. Ocul. Pharmacol. Ther. 2007, 23, 172-181.
-
(2007)
J. Ocul. Pharmacol. Ther
, vol.23
, pp. 172-181
-
-
Becker, U.1
Ehrhardt, C.2
Daum, N.3
Baldes, C.4
Schaefer, U.F.5
Ruprecht, K.W.6
Kim, K.W.7
Lehr, C.M.8
-
71
-
-
35348930627
-
Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport
-
Amioka, K.; Kuzuya, T.; Kushihara, H.; Ejiri, M.; Nitta, A.; Na- beshima, T. Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. J. Pharm. Pharmacol. 2007, 59, 1383-1387.
-
(2007)
J. Pharm. Pharmacol
, vol.59
, pp. 1383-1387
-
-
Amioka, K.1
Kuzuya, T.2
Kushihara, H.3
Ejiri, M.4
Nitta, A.5
Na- beshima, T.6
-
72
-
-
33846105372
-
Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein
-
Obradovic, T.; Dobson, G. G.; Shingaki, T.; Kungu, T.; Hidalgo, I. J. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm. Res. 2007, 24, 318-327.
-
(2007)
Pharm. Res
, vol.24
, pp. 318-327
-
-
Obradovic, T.1
Dobson, G.G.2
Shingaki, T.3
Kungu, T.4
Hidalgo, I.J.5
-
73
-
-
33747891036
-
Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells
-
Manov, I.; Bashenko, Y.; Hirsh, M.; Iancu, T. C. Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells. Basic Clin. Pharmacol. Toxicol. 2006, 99, 213-224.
-
(2006)
Basic Clin. Pharmacol. Toxicol
, vol.99
, pp. 213-224
-
-
Manov, I.1
Bashenko, Y.2
Hirsh, M.3
Iancu, T.C.4
-
74
-
-
0035032962
-
P-glycoprotein efflux pump expression and activity in Calu-3 cells
-
Hamilton, K. O.; Backstrom, G.; Yazdanian, M. A.; Audus, K. L. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J. Pharm. Sci. 2001, 90, 647-658.
-
(2001)
J. Pharm. Sci
, vol.90
, pp. 647-658
-
-
Hamilton, K.O.1
Backstrom, G.2
Yazdanian, M.A.3
Audus, K.L.4
-
75
-
-
33745746815
-
Pharmacological strategies for overcoming multidrug resistance
-
Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7, 861-879.
-
(2006)
Curr. Drug Targets
, vol.7
, pp. 861-879
-
-
Nobili, S.1
Landini, I.2
Giglioni, B.3
Mini, E.4
-
76
-
-
33847148075
-
Paclitaxel-2'- Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity
-
Tanino, T.; Nawa, A.; Kondo, E.; Kikkawa, F.; Daikoku, T.; Tsu- rumi, T.; Luo, C.; Nishiyama, Y.; Takayanagi, Y.; Nishimori, K.; Ichida, S.; Wada, T.; Miki, Y.; Iwaki, M. Paclitaxel-2'- Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. Pharm. Res. 2007, 24, 555-565.
-
(2007)
Pharm. Res
, vol.24
, pp. 555-565
-
-
Tanino, T.1
Nawa, A.2
Kondo, E.3
Kikkawa, F.4
Daikoku, T.5
Tsu- rumi, T.6
Luo, C.7
Nishiyama, Y.8
Takayanagi, Y.9
Nishimori, K.10
Ichida, S.11
Wada, T.12
Miki, Y.13
Iwaki, M.14
|